It is unlikely that low level of BPIFB4 in high severity group may be related to its consumption by the high inflammatory background; rather we hypothesize that based on genotype, or the peculiar stability of the protein, the high circulating level of BPIFB4 characterizing some COVID-19 patients, may induce a homeostatic response and a better tendency to counteract an inflammatory background as seen in the context of “inflammaging” of old individuals. Here, BPIFB4 is linked to COVID-19.